Literature DB >> 26707683

Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.

Yusuke Kawamura1, Yasuji Arase2, Kenji Ikeda3, Norio Akuta3, Masahiro Kobayashi3, Satoshi Saitoh3, Fumitaka Suzuki3, Yoshiyuki Suzuki3, Mie Inao4, Satoshi Mochida4, Hiromitsu Kumada3.   

Abstract

BACKGROUND & AIMS: The effect of ethanol consumption on hepatocarcinogenesis in patients with fatty liver disease (FLD) is not clear. We aimed to investigate the influence of alcohol consumption on hepatocarcinogenesis and determine the risk factors for hepatocellular carcinoma (HCC) in a large number of Japanese patients with FLD without viral hepatitis.
METHODS: This multicenter, retrospective cohort study was conducted at a specialized center for hepatology in Japan and included 9959 patients with FLD without viral hepatitis, diagnosed by ultrasonography from January 1997 through December 2011. The patients' level of ethanol consumption was divided into 4 categories: <20 g/day (n = 6671), 20-39 g/day (n = 753), 40-69 g/day (n = 1589), and ≥70 g/day (n = 946). The primary endpoint was the onset of HCC. Statistical analyses performed included the Kaplan-Meier method and Cox proportional hazard analysis. The median follow-up period was 5.4 years.
RESULTS: Of the study cohort, 49 cases (0.49%) developed HCC during the follow-up period. The annual incidence rate of HCC was 0.05% in patients with FLD and a daily ethanol consumption <20 g/day. Increasing levels of ethanol consumption were associated with increased annual incidence rates of HCC: 0.06% for patients with 20-39 g/day ethanol consumption (hazard ratio [HR], 1.54; 95% confidence interval [CI], 0.34-7.04), 0.16% for patients with 40-69 g/day ethanol consumption (HR, 3.49; 95% CI, 1.50-8.12), and 0.22% for patients with ≥70 g/day ethanol consumption (HR, 10.58; 95% CI, 5.06-22.13), compared with patients with ethanol consumption <20 g/day. Multivariate analysis showed that ethanol consumption ≥40 g/day was an independent risk factor for HCC: for 40-69 g/day the HR was 2.48 (95% CI, 1.01-6.05; P < .047) and for ≥70 g/day the HR was 12.61 (95% CI, 5.68-28.00; P < .001).
CONCLUSIONS: Based on a multicenter, retrospective analysis of almost 10,000 patients with FLD, ethanol consumption ≥40 g/day is an independent risk factor for HCC.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AFLD; Asia; Liver Cancer; NAFLD

Mesh:

Year:  2015        PMID: 26707683     DOI: 10.1016/j.cgh.2015.11.019

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  7 in total

Review 1.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

Review 2.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

3.  Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.

Authors:  Yun Wang; Xiaogang Xiang; Liwen Chen; Zhujun Cao; Rebecca Bao; Huijuan Zhou; Weiliang Tang; Jie Lu; Lanyi Lin; Qing Xie; Shisan Bao; Hui Wang
Journal:  Oncotarget       Date:  2016-09-06

4.  Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study.

Authors:  Jing Sun; Yanfang Li; Yanna Wang; Yanyan Liu; Youde Liu; Xiumei Wang
Journal:  Infect Agent Cancer       Date:  2018-05-22       Impact factor: 2.965

5.  Comprehensive mutational analysis of background mucosa in patients with Lugol-voiding lesions.

Authors:  Naoki Akizue; Kenichiro Okimoto; Makoto Arai; Yosuke Hirotsu; Kenji Amemiya; Hirotaka Oura; Tatsuya Kaneko; Mamoru Tokunaga; Kentaro Ishikawa; Yuki Ohta; Takashi Taida; Keiko Saito; Daisuke Maruoka; Tomoaki Matsumura; Tomoo Nakagawa; Motoi Nishimura; Tetsuhiro Chiba; Kazuyuki Matsushita; Hitoshi Mochizuki; Osamu Yokosuka; Masao Omata; Naoya Kato
Journal:  Cancer Med       Date:  2021-05-02       Impact factor: 4.452

6.  Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.

Authors:  Helen Jarvis; Hannah O'Keefe; Dawn Craig; Daniel Stow; Barbara Hanratty; Quentin M Anstee
Journal:  BMJ Open       Date:  2022-01-04       Impact factor: 2.692

7.  Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis.

Authors:  Ping Zhang; Qingli Liu; Mei Yuan; Lina Wang
Journal:  Infect Agent Cancer       Date:  2018-08-29       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.